Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (41-50 of 437) with videos related to

Pageof 44
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 31, 2018
Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Same…David F Heigener, Martin Reck
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2017
PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?David F Heigener, Martin Reck
Onkologie|June 9, 2012
[Therapeutic standards and perspectives for stage IV non-small cell lung cancer]Martin Reck, Rafael Rosell, Markus Tiemann
Lung Cancer (Amsterdam, Netherlands)|July 24, 2021
KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Wolfram C M Dempke, Martin Reck
Current Opinion in Oncology|January 21, 2015
Novel angiogenesis inhibitors in nonsmall cell lung cancerNiels Reinmuth, David Heigener, Martin Reck
Respiratory Medicine|March 13, 2012
Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysisAndreas Hermes, Benjamin Waschki, Martin Reck
Expert Review of Clinical Pharmacology|August 15, 2014
Nintedanib for the treatment of patients with advanced non-small-cell lung cancerMartin Reck, David Heigener, Niels Reinmuth
European Respiratory Review : an Official Journal of the European Respiratory Society|March 5, 2014
First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodologyMartin Sebastian, Alexander Schmittel, Martin Reck
Future Oncology (London, England)|February 18, 2016
Immunotherapy for small-cell lung cancer: emerging evidenceMartin Reck, David Heigener, Niels Reinmuth
European Journal of Cancer (Oxford, England : 1990)|July 12, 2025
Response to the letter Re: "Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial"Martin Reck, Luis G Paz-Ares
Pageof 44

Showing results (41-50 of 437) with videos related to

Sort By:
Pageof 44
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 31, 2018
Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Same…David F Heigener, Martin Reck
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 25, 2017
PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?David F Heigener, Martin Reck
Onkologie|June 9, 2012
[Therapeutic standards and perspectives for stage IV non-small cell lung cancer]Martin Reck, Rafael Rosell, Markus Tiemann
Lung Cancer (Amsterdam, Netherlands)|July 24, 2021
KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Wolfram C M Dempke, Martin Reck
Current Opinion in Oncology|January 21, 2015
Novel angiogenesis inhibitors in nonsmall cell lung cancerNiels Reinmuth, David Heigener, Martin Reck
Respiratory Medicine|March 13, 2012
Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysisAndreas Hermes, Benjamin Waschki, Martin Reck
Expert Review of Clinical Pharmacology|August 15, 2014
Nintedanib for the treatment of patients with advanced non-small-cell lung cancerMartin Reck, David Heigener, Niels Reinmuth
European Respiratory Review : an Official Journal of the European Respiratory Society|March 5, 2014
First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodologyMartin Sebastian, Alexander Schmittel, Martin Reck
Future Oncology (London, England)|February 18, 2016
Immunotherapy for small-cell lung cancer: emerging evidenceMartin Reck, David Heigener, Niels Reinmuth
European Journal of Cancer (Oxford, England : 1990)|July 12, 2025
Response to the letter Re: "Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial"Martin Reck, Luis G Paz-Ares
Pageof 44